- Home
- MGLD vs NRXP Comparison
MGLD vs NRXP Comparison
Compare MGLD & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- NRXP
- Stock Information
- Founded
- MGLD 1996
- NRXP 2015
- Country
- MGLD United States
- NRXP United States
- Employees
- MGLD N/A
- NRXP N/A
- Industry
- MGLD Finance/Investors Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- NRXP Health Care
- Exchange
- MGLD Nasdaq
- NRXP Nasdaq
- Market Cap
- MGLD 35.8M
- NRXP 32.6M
- IPO Year
- MGLD N/A
- NRXP N/A
- Fundamental
- Price
- MGLD $1.00
- NRXP $3.29
- Analyst Decision
- MGLD
- NRXP Strong Buy
- Analyst Count
- MGLD 0
- NRXP 4
- Target Price
- MGLD N/A
- NRXP $28.50
- AVG Volume (30 Days)
- MGLD 12.6K
- NRXP 284.9K
- Earning Date
- MGLD 05-08-2025
- NRXP 08-13-2025
- Dividend Yield
- MGLD N/A
- NRXP N/A
- EPS Growth
- MGLD N/A
- NRXP N/A
- EPS
- MGLD N/A
- NRXP N/A
- Revenue
- MGLD $31,205,000.00
- NRXP N/A
- Revenue This Year
- MGLD N/A
- NRXP N/A
- Revenue Next Year
- MGLD N/A
- NRXP N/A
- P/E Ratio
- MGLD N/A
- NRXP N/A
- Revenue Growth
- MGLD N/A
- NRXP N/A
- 52 Week Low
- MGLD $0.70
- NRXP $1.10
- 52 Week High
- MGLD $2.10
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- MGLD 58.23
- NRXP 60.87
- Support Level
- MGLD $0.80
- NRXP $3.14
- Resistance Level
- MGLD $1.04
- NRXP $3.61
- Average True Range (ATR)
- MGLD 0.07
- NRXP 0.26
- MACD
- MGLD 0.01
- NRXP -0.02
- Stochastic Oscillator
- MGLD 77.67
- NRXP 53.17
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.